SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): April 2, 2019
Aileron Therapeutics, Inc.
(Exact Name of Company as Specified in Charter)
(State or Other Jurisdiction
490 Arsenal Way
|(Address of Principal Executive Offices)||(Zip Code)|
Registrants telephone number, including area code: (617) 995-0900
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions ( see General Instruction A.2. below):
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☒
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
On April 2, 2019, Nolan Sigal, M.D., Ph.D. was elected to the Board of Directors (the Board) of Aileron Therapeutics, Inc. (the Company) as a Class II director with a term expiring at the 2019 annual meeting of stockholders, effective upon the closing of the Companys previously announced private placement. The Board also appointed Dr. Sigal to serve on the Boards Compensation Committee and Nominating and Corporate Governance Committee.
Dr. Sigal currently serves as a partner at Satter Management Co., L.P., a private investment firm, a position he has held since January 2018. From March 2008 to December 2017, Dr. Sigal was the president and chief executive officer of Tunitas Therapeutics, Inc., a private biopharmaceutical company. Prior to 2008, Dr. Sigal held various leadership positions with several public and private pharmaceutical and biotechnology companies, including several management positions at Merck & Company. Dr. Sigal received an A.B. from Princeton University and an M.D. and Ph.D. from the University of Pennsylvania School of Medicine.
Dr. Sigal was appointed to the Board and each Board committee pursuant to the terms of the Securities Purchase Agreement, dated as of March 28, 2019, between the Company and the Investors party hereto, relating to a previously announced private placement of securities. The Board also determined to nominate Dr. Sigal for election as a Class II director at the 2019 annual meeting of stockholders and to recommend that the stockholders of the Company vote for his election as a Class II director at the 2019 annual meeting of stockholders.
Dr. Sigal has no family relationships with any director, executive officer or any person nominated or chosen by the Company to become a director or executive officer.
In accordance with the Companys director compensation program, Dr. Sigal will receive an annual cash fee of $35,000 for service on the Board and an additional cash fee of $10,000 and $7,500 for service on the Boards Compensation Committee and Nominating and Corporate Governance Committee, respectively, which fees are payable in arrears in four quarterly installments on the last day of each calendar quarter. In addition, under the Companys director compensation program, upon his election as a director, Dr. Sigal was granted an option on April 2, 2018 to purchase 20,000 shares of the Companys common stock at an exercise price of $1.82. This option vests in three equal annual installments from his initial election and becomes exercisable in full upon the occurrence of a change of control of the Company.
In connection with his appointment to the Board, Dr. Sigal also entered into the Companys standard form of indemnification agreement, a copy of which was filed as Exhibit 10.12 to Amendment No. 1 to the Companys Registration Statement on Form S-1 (File No. 333-218474) filed with the Securities and Exchange Commission on June 19, 2017. Pursuant to the terms of this agreement, the Company may be required, among other things, to indemnify Dr. Sigal for some expenses, including attorneys fees, judgments, fines and settlement amounts incurred by him in any action or proceeding arising out of his service as a director of the Company.
On April 3, 2019, the Company issued a press release announcing the closing of a previously announced private placement of an aggregate of (i) 11,838,582 units, consisting of 11,838,582 shares of the Companys common stock, par value $0.001 per share and associated warrants to purchase an aggregate of 11,838,582 shares of common stock, for a combined price of $2.01 per unit and (ii) 1,096,741 units, consisting of pre-funded warrants to purchase 1,096,741 shares of the Companys common stock and associated Common Warrants to purchase 1,096,741 shares of common stock, for a combined price of $2.01 per unit.
The private placement resulted in gross proceeds of approximately $26.0 million to the Company, before deducting placement agent fees and offering expenses, and excluding the exercise price of any warrants. The full text of the press release issued in connection with this announcement is attached as Exhibit 99.1 to this Form 8-K and incorporated herein by reference.
Financial Statements and Exhibits.
|99.1||Press Release, dated April 3, 2019|
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|Aileron Therapeutics, Inc.|
|Date: April 3, 2019||By:||/s/ Donald V. Dougherty|
|Donald V. Dougherty|
|Chief Financial Officer|
Aileron Therapeutics Completes $26M Private Placement
Satter Medical Technology Partners led the private placement; Dr. Nolan Sigal, Partner at Satter
Management, joins Ailerons Board of Directors
Watertown, Mass., April 3, 2019 (GLOBE NEWSWIRE) Aileron Therapeutics (NASDAQ: ALRN), the clinical-stage leader in the field of stabilized cell-permeating peptides to treat cancer and other diseases, announced today the closing of its previously announced private placement of Aileron common stock and warrants, resulting in gross proceeds of $26 million, before deducting placement agent fees and offering expenses, and excluding the exercise of any warrants.
The private placement was led by Satter Medical Technology Partners, L.P. Additional participants included Jennison Associates (on behalf of certain clients) and an undisclosed institutional investor, in addition to other new and existing investors.
In connection with this financing, Aileron also announced that Dr. Nolan Sigal, a Partner at Satter, has joined Ailerons Board of Directors.
Dr. Sigal has served as a partner at Satter Management, a private investment firm, since January 2018. From March 2008 to December 2017, Dr. Sigal was the president and chief executive officer of Tunitas Therapeutics, Inc., a private biopharmaceutical company. Prior to 2008, Dr. Sigal held various leadership positions with several public and private pharmaceutical and biotechnology companies, including Merck & Company, Trellis, Cytokinetics, and Pharmacopeia. Dr. Sigal received an A.B. from Princeton University and an M.D. and Ph.D. from the University of Pennsylvania School of Medicine.
I believe that the application of Ailerons proprietary peptide drug, ALRN-6924, in the indications of MDM2-amplified tumors (with Pfizers Ibrance®) and myelopreservation represent compelling opportunities. As a member of the Board of Directors, I look forward to helping the Company as it seeks to create value for its shareholders through the advancement of these programs, stated Nolan Sigal, M.D., Ph.D.
We expect that the proceeds from this closing will enable Aileron to achieve key clinical data readouts said Dr. Manuel Aivado, M.D, Ph.D., CEO & President of Aileron. We expect the addition of Dr. Sigal to our Board of Directors to play an important role in our success. His extensive research experience as an executive in the biotech industry makes him a welcome addition to the Aileron team.
In the private placement the Company sold 11,838,582 units, consisting of 11,838,582 shares of common stock and associated warrants to purchase 11,838,582 shares of common stock, for a combined price of $2.01 per unit. In addition, the Company also sold 1,096,741 units, consisting of pre-funded warrants to purchase 1,096,741 shares of common stock and associated warrants to purchase 1,096,741 shares of common stock, for a combined price of $2.01 per unit.
William Blair & Company, L.L.C. acted as sole placement agent in connection with the financing.
Aileron expects to use the net proceeds from the financing to fund the further advancement of its ALRN-6924 clinical trials and research programs, including its ongoing clinical trial collaboration with Pfizer testing ALRN-6924 in combination with palbociclib in MDM2-amplified cancers and its planned Phase 1b/2 clinical trial to evaluate ALRN-6924 as a myelopreservative agent to protect against chemotherapy-induced toxicity. This use of proceeds reflects Ailerons decision to cease enrollment and clinical development in AML/MDS in light of the Companys resources and its re-assessment of the commercial opportunities in AML/MDS considering the rapidly evolving competitive landscape in this field.
The securities sold in the private placement have not been registered under the Securities Act of 1933, as amended (the Securities Act), or applicable state securities laws, and accordingly may not be offered or sold in the United States except pursuant to an effective registration statement or an applicable exemption from the registration requirements of the Securities Act and such applicable state securities laws. Aileron has agreed to file a registration statement with the Securities and Exchange Commission registering the resale of the shares of common stock issued in the private placement and the shares of common stock issuable upon the exercise of the warrants issued in the private placement.
This release does not constitute an offer to sell or the solicitation of an offer to buy the securities, nor shall there be any sale of the securities in any state in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of such state. Any offering of the securities under the resale registration statement will only be by means of a prospectus.
Aileron is a clinical-stage biopharmaceutical company advancing a proprietary platform of cell-permeating alpha-helical peptides that address the most important intracellular targets in oncology and other therapeutic areas. Its most advanced product candidate, ALRN-6924, is a first-in-class, clinical-stage, stabilized cell-permeating alpha-helical peptide that mimics the p53 tumor suppressor protein to disrupt its interactions with MDM2 and MDMX and, for p53 wild-type tumors, can restore p53-dependent tumor suppression. ALRN-6924 is currently being evaluated in multiple clinical trials for the treatment of various cancers, including MDM2-amplified cancers.
Statements in this press release about Ailerons future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, including
statements about the expected closing of the private placement, Ailerons financial prospects, anticipated use of proceeds, and future operations and sufficiency of funds for future operations, may constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, statements about the Companys strategy, financing, and clinical development plans. The words anticipate, believe, continue, could, estimate, expect, intend, may, plan, potential, predict, project, should, target, would and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words.
Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including whether Ailerons cash resources will be sufficient to fund its continuing operations for the periods and/or trials anticipated; whether results obtained in preclinical studies and clinical trials will be indicative of results obtained in future clinical trials; whether Ailerons product candidates will advance through the clinical trial process on a timely basis, or at all; whether the results of such trials will warrant submission for approval from the United States Food and Drug Administration or equivalent foreign regulatory agencies; whether Ailerons product candidates will receive approval from regulatory agencies on a timely basis or at all; whether, if product candidates obtain approval, they will be successfully distributed and marketed; whether the Company will be able to enter into additional collaborations; and other factors discussed in the Risk Factors section of Ailerons annual report on Form 10-K for the period ended December 31, 2018, filed on March 29, 2019, and risks described in other filings that Aileron may make with the Securities and Exchange Commission. Any forward-looking statements contained in this press release speak only as of the date hereof, and Aileron specifically disclaims any obligation to update any forward-looking statement, whether because of new information, future events or otherwise.
Don Dougherty, CFO
Hans C. Vitzthum
LifeSci Advisors, LLC.